Conduit Pharmaceuticals Inc. (CDT)
NASDAQ: CDT · Real-Time Price · USD
0.0720
-0.0018 (-2.44%)
At close: Jan 17, 2025, 4:00 PM
0.0737
+0.0017 (2.36%)
After-hours: Jan 17, 2025, 7:59 PM EST
Conduit Pharmaceuticals Employees
Conduit Pharmaceuticals had 7 employees as of December 31, 2023.
Employees
7
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,164,429
Market Cap
8.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
CDT News
- 5 weeks ago - Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics - GlobeNewsWire
- 2 months ago - Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders - GlobeNewsWire
- 2 months ago - Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors - GlobeNewsWire
- 2 months ago - Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline - GlobeNewsWire
- 2 months ago - Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes - GlobeNewsWire
- 5 months ago - Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders - GlobeNewsWire
- 5 months ago - Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments - GlobeNewsWire
- 8 months ago - AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 - Business Wire